Table 1. Case analysis of literature on adverse skin reaction caused by sintilimab.

Number	Sex	Age (years)	Cancer	Immunotherapy regimen	Dose	Occurrence time	Initial symptom	Treatment	Stop/start sintilimab	Outcome of adverse event
1 (2)	Male	55	Lung adenocarcinoma	Sintilimab, pemetrexed, carboplatin	200 mg, q21d	44 days after the first cycle	Dermatitis bullosa	Piperacillin tazobactam, fusidic acid cream, and cetirizine, prednisone tablets	Stop	Survived
2 (3)	Male	64	Cancer of the esophagogastric junction	Sintilimab	200 mg, q21d	5 days after the first cycle	Purpura like cutaneous vasculitis	Methylprednisolone and diphenhydramine	Stop	Death
3 (4)	Male	72	Lung cancer, hepatopulmonary metastases	Sintilimab, paclitaxel liposome, carboplatin	200 mg/kg, q21d	23 days after the first cycle	Toxic epidermal necrolysis	Methylprednisolone sodium succinate injection and prednisone acetate tablets	Stop	Survived
4 (5)	Male	65	Lymphoma	Sintilimab, gemcitabine, oxaliplatin	200 mg, q21d	11 days after the first cycle	Toxic epidermal necrosis	Oral cetirizine, methylprednisolone, immunoglobulin, piperacillin sodium/tazobactam, and parenteral nutrition	Stop	Survived
5 (6)	Female	72	Gallbladder carcinoma	Sintilimab, anlotinib	Not mentioned	2 weeks after receiving 1 dose of sintilimab	Toxic epidermal necrolysis	Methylprednisolone, immunoglobulin, albumin, encapsulation, tapering of glucocorticoid, and oral nystatin	Stop	Survived